Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.850
-0.030 (-0.61%)
At close: Sep 25, 2026, 4:00 PM EDT
4.860
+0.010 (0.21%)
After-hours: Sep 25, 2026, 7:57 PM EDT
Arbutus Biopharma Employees
Arbutus Biopharma had 19 employees as of December 31, 2025. The number of employees decreased by 25 or -56.82% compared to the previous year.
Employees
19
Change (1Y)
-25
Growth (1Y)
-56.82%
Revenue / Employee
$9,564,211
Profits / Employee
$8,055,474
Market Cap
959.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -25 | -56.82% | 19 | 0 |
| Dec 31, 2024 | 44 | -29 | -39.73% | 44 | 0 |
| Dec 31, 2023 | 73 | -25 | -25.51% | 73 | 0 |
| Dec 31, 2022 | 98 | 11 | 12.64% | 96 | 2 |
| Dec 31, 2021 | 87 | 9 | 11.54% | 85 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| Alumis | 239 |
| Monte Rosa Therapeutics | 173 |
| Janux Therapeutics | 113 |
| Adlai Nortye Group | 109 |
| Cullinan Therapeutics | 109 |
| Odyssey Therapeutics | 100 |
| Cybin | 100 |
ABUS News
- 4 weeks ago - Arbutus Biopharma commences $230M modified Dutch Auction tender offer - TheFly
- 4 weeks ago - Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share - GlobeNewsWire
- 5 weeks ago - Arbutus Biopharma to repurchase $230M of shares through Dutch Auction - TheFly
- 5 weeks ago - Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer - GlobeNewsWire
- 6 weeks ago - Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Arbutus Biopharma Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Arbutus Biopharma Earnings release: Q2 2026 - Filings
- 2 months ago - Arbutus Biopharma expects to return $230M in capital to shareholders - TheFly